Type 2 Diabetic Medication Regimen in Treating Depression and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Veterans Using PHQ-9 and FIB-4 Scores

被引：0
|
作者：
Ubalde, Shannen Nicole
Khoury, Jessica
Davis, Jessica
Sen, Sabyasachi
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1889-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1889-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Serial Liver Stiffness Measurement and Fibrosis-4 Scores in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Goyal, Tanvi
    Song, Michael W.
    Suresh, Deepika
    Jasty, Venkata S. J.
    Urias, Esteban
    Wijarnpreecha, Karn
    Wong, Yu Jun
    Chen, Vincent L.
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (11) : 4250 - 4258
  • [22] FIB-4 score as a predictor of mortality outcomes in individuals with metabolic dysfunction-associated steatotic liver disease with moderate alcohol consumption: a nationwide cohort study
    Aboona, Majd
    Danpanichkul, Pojsakorn
    Chen, Vincent
    Rangan, Pooja
    Kim, Donghee
    Alkhouri, Naim
    Noureddin, Mazen
    Arab, Juan Pablo
    Wijarnpreecha, Karn
    JOURNAL OF HEPATOLOGY, 2024, 80 : S146 - S146
  • [23] EFFICACY AND SAFETY OF RESMETIROM IN TREATING PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A SYSTEMATIC REVIEW AND META-ANALYSIS
    Ekreer, Moad
    Al Hayek, Mohammad
    Alhateem, Mohamed Salah
    Khashan, Abdallah
    Abeedah, Raja
    Aghneewah, Omar
    Abduljawad, Fatimah Alzahra
    Elhadi, Muhammed
    HEPATOLOGY, 2024, 80
  • [24] Assessing the diagnostic accuracy of ChatGPT-4 in the histopathological evaluation of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD)
    Akpinar, Reha
    Laohawetwanit, Thiyaphat
    Panzeri, Davide
    De Carlo, Camilla
    Belsito, Vincenzo
    Terracciano, Luigi
    Aghemo, Alessio
    Pugliese, Nicola
    Calderaro, Julien
    Sironi, Laura
    Di Tommaso, Luca
    JOURNAL OF HEPATOLOGY, 2024, 80 : S580 - S580
  • [25] Oral insulin therapy for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes
    Kahl, S.
    DIABETOLOGIE, 2024, : 902 - 903
  • [26] Effects of SGLT2i and Pioglitazone on FIB-4 Index in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)-A Real World Retrospective Study from India
    Padhye, Dakshata
    Seshadri, Krishna
    DIABETES, 2024, 73
  • [27] Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes
    Ciardullo, Stefano
    Perseghin, Gianluca
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 97 - 98
  • [28] Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
    Abdelhameed, Farah
    Kite, Chris
    Lagojda, Lukasz
    Dallaway, Alexander
    Chatha, Kamaljit Kaur
    Chaggar, Surinderjeet S.
    Dalamaga, Maria
    Kassi, Eva
    Kyrou, Ioannis
    Randeva, Harpal S.
    CURRENT OBESITY REPORTS, 2024, 13 (03): : 510 - 531
  • [29] Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes
    Cernea, Simona
    Onisor, Danusia
    Roiban, Andrada Larisa
    Benedek, Theodora
    Rat, Nora
    WORLD JOURNAL OF CARDIOLOGY, 2024, 16 (10):
  • [30] Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis
    Jamil, Asma
    Chivese, Tawanda
    Elshaikh, Usra
    Sendall, Marguerite
    BMC PUBLIC HEALTH, 2024, 24 (01)
12345